Biotechnology company UbiVac will collaborate with Johnson & Johnson Innovation to develop and test an oral cancer vaccine.
The effort will include Janssen Biotech, a Johnson & Johnson company, according to the companies.
UbiVac will develop new preclinical and clinical versions of its proprietary DRibble immunotherapy for use in preclinical studies of oral cancer. The company will receive an upfront payment, plus additional financial commitments, contingent upon reaching certain predetermined research, development, and manufacturing milestones. Janssen has an option for further development and licensing of the new DRibble immunotherapy.
"We are excited about this collaboration with Janssen to evaluate UbiVac's DRibble technology as a potential approach for intercepting oral cancer," stated Bernard Fox, CEO of UbiVac, in a press release.
